Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies

Autor(es)

Gewehr, Mayara C. F. ^[1] ; Silverio, Renata ^[2] ; Rosa-Neto, Jose Cesar ^[3] ; Lira, Fabio S. ^[4] ; Reckziegel, Patricia ^[5] ; Ferro, Emer S. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Biomed Sci Inst, Dept Pharmacol, Sao Paulo 05508000 - Brazil

^[2] Fed Univ Santa Catarina UFSC, Ctr Biol Sci, Dept Pharmacol, Florianopolis 88040900, SC - Brazil

^[3] Univ Sao Paulo, Biomed Sci Inst, Dept Cell & Dev Biol, Sao Paulo 05508000 - Brazil

^[4] Sao Paulo State Univ UNESP, Dept Phys Educ, Presidente Prudente 19060900 - Brazil

^[5] Fed Univ Sao Paulo UNIFESP, Natl Inst Pharmacol & Mol Biol INFAR, Dept Pharmacol, Sao Paulo 05508000 - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Molecules; v. 25, n. 5 MAR 1 2020.
• Citações Web of Science: 0

Resumo

Overweight and obesity are among the most prominent health problems in the modern world, mostly because they are either associated with or increase the risk of other diseases such as type 2 diabetes, hypertension, and/or cancer. Most professional organizations define overweight and obesity according to individual body-mass index (BMI, weight in kilograms divided by height squared in meters). Overweight is defined as individuals with BMI from 25 to 29, and obesity as individuals with BMI >= 30. Obesity is the result of genetic, behavioral, environmental, physiological, social, and cultural factors that result in energy imbalance and promote excessive fat deposition. Despite all the knowledge concerning the pathophysiology of obesity, which is considered a disease, none of the existing treatments alone or in combination can normalize blood glucose concentration and prevent debilitating complications from obesity. This review discusses some new perspectives for overweight and obesity treatments, including the use of the new orally active cannabinoid peptide Pep19, the advantage of which is the absence of undesired central nervous system effects usually experienced with other cannabinoids. (AU)

• Processo FAPESP: 16/04000-3 - Farmacologia de oligopeptidases e peptídeos intracelulares
• Beneficiário: Emer Suavinho Ferro
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/20657-0 - Avaliação do potencial uso farmacológico da hemopressina (HP) no tratamento da obesidade
• Beneficiário: Patrícia Reckziegel
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado